, We thank surgeons and pathologists at Henri Mondor hospital (APHP
Claire Castaing at Bordeaux Hospital; the "Réseau Français des biobanques des tumeurs hépatiques" Bruno Clément, Valérie Paradis, Thomas Decaens, Simone Mathoulin-Pelissier; the Cancer Biobank of CHU Bordeaux, no. BRIF: BB-0033-00036 and CHU Henri Mondor for contributing to the tissue collection. We thank Floriane Bard, Caroline Lecerf, Bérengère Ouine and Audrey Criqui for performing the RPPA experiments. We warmly thank Frédéric Soysouvanh for help in drug screening ,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, pp.359-86, 2015. ,
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, vol.10, pp.25-34, 2009. ,
Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-90, 2008. ,
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, vol.389, pp.56-66, 2017. ,
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity, Molecular cancer therapeutics, vol.9, pp.1544-53, 2010. ,
Met as a therapeutic target in HCC: facts and hopes, J Hepatol, vol.60, pp.442-52, 2014. ,
,
, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-516, 2015.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma, Hepatology, vol.58, pp.706-723, 2013. ,
,
, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, Lancet Oncol, vol.14, pp.55-63, 2013.
,
ARQ197) displays cytotoxic activity that is independent of its ability to bind MET, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.19, pp.2381-92, 2013. ,
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines, Mol Oncol, vol.9, pp.260-269, 2015. ,
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition, Cancer Res, vol.73, pp.3087-96, 2013. ,
Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma, J Exp Clin Cancer Res, vol.34, p.118, 2015. ,
New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis, British journal of cancer, vol.99, pp.151-160, 2008. ,
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, vol.145, pp.176-87, 2013. ,
NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PloS one, vol.7, p.38686, 2012. ,
,
, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, pp.42-52, 2007.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions, Nat Commun, vol.4, p.2218, 2013. ,
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas, Mod Pathol, vol.26, pp.1632-1673, 2013. ,
,
, A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis, British journal of cancer, vol.108, pp.21-25, 2013.
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.29, pp.1271-1280, 2011. ,
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival, Cancer Res, vol.67, pp.2081-2089, 2007. ,
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.20, pp.2959-70, 2014. ,
Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo, Molecular cancer therapeutics, vol.4, pp.1577-84, 2005. ,
Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib, Eur Urol, vol.67, pp.353-357, 2015. ,
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197, The Journal of biological chemistry, vol.286, pp.20666-76, 2011. ,
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma, PloS one, vol.9, p.105919, 2014. ,
ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1, Oncotarget, vol.6, pp.22167-78, 2015. ,
Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition, Neuroendocrinology, vol.103, pp.383-401, 2016. ,
Off-target effects of c-MET inhibitors on thyroid cancer cells, Molecular cancer therapeutics, vol.13, pp.134-177, 2014. ,
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer, BMC Cancer, vol.14, p.550, 2014. ,
Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients, J Breast Cancer, vol.17, pp.40-46, 2014. ,
Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?, Surgery, vol.155, pp.927-962, 2014. ,
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients, British journal of cancer, vol.78, pp.34-43, 1998. ,
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response, Am J Clin Pathol, vol.113, pp.355-63, 2000. ,
The multiple facets of drug resistance: one history, different approaches, J Exp Clin Cancer Res, vol.33, p.37, 2014. ,
Multidrug resistance in cancer: role of ATPdependent transporters, Nat Rev Cancer, vol.2, pp.48-58, 2002. ,
ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance, Molecular cancer therapeutics, vol.13, pp.2978-90, 2014. ,
Tivantinib (ARQ197) in hepatocellular carcinoma, Expert review of anticancer therapy, vol.15, pp.615-637, 2015. ,
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling, Proc Natl Acad Sci U S A, vol.104, pp.19936-19977, 2007. ,
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752, Proc Natl Acad Sci, vol.103, pp.2316-2337, 2006. ,
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.21, pp.2297-304, 2015. ,